Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study
CNS relapse in LDCGB
DOI:
https://doi.org/10.31053/1853.0605.v78.n2.28183Keywords:
lymphoma, non-hodgkin, lymphoma, large b-cell, diffuse, neoplasm recurrence, localAbstract
Introduction: CNS relapse in patients with LDCGB is a poor prognosis event. The incidence of relapse is variable according to the literature. Data in Latin America is lacking.
Methods: In order to establish the incidence of CNS relapse in our cohort, time to CNS relapse and the impact of CNS relapse risk factors, a retrospective cohort study was performed, from January 2012 to June 2017.
Results: One hundred and forty seven patients were analyzed. The median age was 66 years (ICR 56-76); 76 patients (51.70%) were men. The IPI was low or intermediate/low in 115 (78.2%) cases. The CNS IPI was intermediate in 77 (52.4%) and high in 14 (9.5%) of cases. Thirty-five (23.81%) patients received intrathecal prophylaxis. No patient received systemic prophylaxis. During the follow-up, 8 (4.59%) patients had CNS relapse, none of them with high IPI. The median time to relapse was 6.5 months (ICR 5.5-10). Seven (87.5%) patients relapsed within the year of diagnosis. We found no risk factors for CNS involvement in the bivariate analysis. The incidence of relapse was 2.7% (CI 0.2% -4.6%), 4.8% (CI 1.8% -8.9%) and 5.4% (CI 4.5- 8.9%) at 6, 12 and 24 months, respectively.
Discussion: The incidence of CNS relapse was similar to that described in the international series. Our study confirms that the majority of patients relapse during the first year of follow up. We must carry out broader collaborative work to better establish the risk factor for CNS relapse.
Downloads
References
2. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380: 848–857.
3. Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin’s Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516—The Southwest Oncology Group. Journal of Clinical Oncology. 2009. pp. 114–119. doi:10.1200/jco.2008.16.8021
4. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009. pp. 3896–3902. doi:10.1182/blood-2008-10-182253
5. Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis—A Systematic Review of Prospective Studies. Clinical Lymphoma Myeloma and Leukemia. 2015. pp. 451–457. doi:10.1016/j.clml.2015.02.026
6. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology. 2016. pp. 3150–3156. doi:10.1200/jco.2015.65.6520
7. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55: 509–514.
8. Eyre TA, Djebbari F, Kirkwood AA, Collins GP. A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era. Haematologica. 2019. doi:10.3324/haematol.2019.229948
9. Feugier P. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology. 2004. pp. 129–133. doi:10.1093/annonc/mdh013
10. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology. 2010. pp. 1046–1052. doi:10.1093/annonc/mdp432
11. McMillan A, Ardeshna KM, Cwynarski K, Lyttelton M, McKay P, Montoto S. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. British Journal of Haematology. 2013. doi:10.1111/bjh.12509
12. Cheah CY, Herbert KE, O’Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer. 2014. pp. 1072–1079. doi:10.1038/bjc.2014.405
13. Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Annals of Oncology. 2012. pp. 1267–1273. doi:10.1093/annonc/mdr440
14. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127: 2375–2390.
15. da Rocha TMB da S, Sérgio Costa F, Pinto MSG, da Silva IC, Paes RP, Chiattone CS. Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter. 2013;35: 256–262.
16. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010. pp. 4283–4290. doi:10.1002/cncr.25278
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
